Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Armand

Showing results (151-160 of 273) with videos related to

Pageof 28
Sort By:
Blood|December 17, 2015
Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHDAna C Alho, Haesook T Kim, Marie J Chammas, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 15, 2018
Impact of Thrombotic Microangiopathy on Renal Outcomes and Survival after Hematopoietic Stem Cell TransplantationMerve Postalcioglu, Haesook T Kim, Faruk Obut, et al.
Haematologica|May 27, 2014
Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantationKazuyuki Murase, Haesook T Kim, O R Gregory Bascug, et al.
Blood Advances|April 3, 2019
Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host diseaseJennifer S Whangbo, Haesook T Kim, Sarah Nikiforow, et al.
Blood Advances|November 15, 2024
A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphomaAndrew Looka, David A Qualls, Daniel Matthews, et al.
British Journal of Cancer|December 14, 2020
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphomaGeoffrey I Shapiro, Patricia LoRusso, Afshin Dowlati, et al.
British Journal of Haematology|August 16, 2023
Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvementChristine E Ryan, Rebecca L Zon, Robert Redd, et al.
Blood Advances|August 15, 2023
Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 studyAdam J Olszewski, Tycel J Phillips, Marc S Hoffmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2019
Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II StudyStephen M Ansell, Monique C Minnema, Peter Johnson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 27, 2015
Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk LymphomaYi-Bin Chen, Shuli Li, David C Fisher, et al.
Pageof 28

Showing results (151-160 of 273) with videos related to

Sort By:
Pageof 28
Blood|December 17, 2015
Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHDAna C Alho, Haesook T Kim, Marie J Chammas, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 15, 2018
Impact of Thrombotic Microangiopathy on Renal Outcomes and Survival after Hematopoietic Stem Cell TransplantationMerve Postalcioglu, Haesook T Kim, Faruk Obut, et al.
Haematologica|May 27, 2014
Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantationKazuyuki Murase, Haesook T Kim, O R Gregory Bascug, et al.
Blood Advances|April 3, 2019
Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host diseaseJennifer S Whangbo, Haesook T Kim, Sarah Nikiforow, et al.
Blood Advances|November 15, 2024
A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphomaAndrew Looka, David A Qualls, Daniel Matthews, et al.
British Journal of Cancer|December 14, 2020
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphomaGeoffrey I Shapiro, Patricia LoRusso, Afshin Dowlati, et al.
British Journal of Haematology|August 16, 2023
Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvementChristine E Ryan, Rebecca L Zon, Robert Redd, et al.
Blood Advances|August 15, 2023
Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 studyAdam J Olszewski, Tycel J Phillips, Marc S Hoffmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2019
Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II StudyStephen M Ansell, Monique C Minnema, Peter Johnson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 27, 2015
Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk LymphomaYi-Bin Chen, Shuli Li, David C Fisher, et al.
Pageof 28